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A BST R AC T   
 
Aim: To investigate whether there is a relationship between both massive and sub-massive pulmonary 
embolism (PE) and eosinophil counts in order to evaluate it as a predictor factor.  
Methods: This retrospective study included 108 patients (64 sub-massive and 44 massive) who received both 
tomographic and clinical diagnoses of pulmonary embolism, and 75 subjects served as controls. Hemogram 
parameters were compared between patients with massive and sub-massive pulmonary embolism and those of 
control groups. 
Results: In terms of white blood cell and eosinophil counts, the lowest value was evident in the massive PE 
group whereas the control group had the highest value. The eosinophil counts increased significantly one week 
after the treatment when compared to those at the presentation with PE (0.112 (0.003-0.853) vs. (0.144 (0.011-
0.914), p=0.01). Spearman correlation test showed a significant positive correlation between right ventricular 
dysfunction or elevated cardiac troponin level and massive PE (r=0.54, p <0.001), whereas a negative 
correlation was detected between eosinophil count and the presence of massive PE (r=-0.36, p<0.001). 
Conclusion: The results of our study suggest that lower eosinophil counts may lead a physician to suggest a 
higher probability of acute massive pulmonary embolism rather than sub-massive pulmonary embolism. 
However, further randomized studies are required to confirm these findings. 
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Introduction 
Pulmonary embolism (PE) is characterized by 
an occlusion of pulmonary arteries. Acute PE is 
a life-threatening condition that needs 
immediate treatment to prevent death [1]. The 
severity and prognosis of PE depend on the 
involvement degree of the pulmonary arterial 
bed [2,3].  
Identification of predisposing factors and 
markers for PE is crucial for determining the 
treatment modality. Eosinophils are the 2nd 
largest member of the leukocyte family [4]. 
They have been associated with allergic 
diseases, parasitic infections, autoimmune 
diseases, and myelodysplastic syndrome [4]. In 
addition, evidence has shown that eosinophils 
are associated with stent thrombosis, 
vasospastic angina, coronary artery disease, and 
coronary collateral development [4-6]. 
Eosinophils are known to comprise many 
granules facilitating both the formation and 
growth of thrombus in several diseases [7,8]. 
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However, the literature lacks data from the 
comparison of eosinophil counts between 
patients with massive and sub-massive PE. 
Strong vasoactive and pro-coagulant effects of 
eosinophils suggest a relationship between 
eosinophil counts and pulmonary thrombus 
formation. In this study, to investigate the 
relationship of eosinophil counts with massive 
and submassive PE and also to reveal whether 
it can be used as a predictor. 
 
Materials and methods 
In this single-center study, we analyzed 
retrospectively 108 patients with PE and 75 
healthy control subjects who were admitted to 
Bolu Abant Izzet Baysal University Hospital 
between January 2018 and July 2019. The study 
was approved by the Ethics committee of Bolu 
Abant Izzet Baysal University (Date and 
Decision no: 2020-168). Patients’ demographic 
data such as age, weight, sex, height, heart rate, 
blood pressure, medication, comorbidity, 
smoking, and laboratory parameters were 
extracted from the electronic medical record. 
Hemogram values were obtained at initial 
presentation and after treatment.  
Patients who had blood pressure ≥140 / 90 
mmHg or use antihypertensive drugs were 
considered as having hypertension (HT). 
Diabetes mellitus (DM) was determined by the 
current use of antidiabetic drugs, fasting blood 
glucose level > 126 mg/dl, or HbA1c ≥7. Those 
who had a total cholesterol level ≥200 mg/dL, 
LDL-c level ≥130 mg/dL, or use of cholesterol-
lowering medication were considered as having 
hyperlipidemia (HL). An individual who was 
active smoker or had a smoking history of > 10 
packs per year was considered a smoker. 
For diagnosing and determining the severity of 
PE, we leveraged current guidelines including 
symptoms, high D-dimer level, 
electrocardiogram, computed tomography 
pulmonary angiogram (CTPA), 
echocardiography, and positive cardiac 
enzymes [9]. Radiological data allowed us to 
distinguish between massive and sub-massive 
PE. From the radiological point of view, a 
massive PE is described as a reduction of lung 
perfusion in one lung (> 90%) or total occlusion 
of a main pulmonary artery diagnosed with a 
CTPA. The remaining forms are described as 
sub-massive PE [10]. 
Patients were excluded from the study for the 
following reasons: pregnancy, systemic 
inflammatory or infectious disease, chronic 
obstructive pulmonary disease, any known 
hematological disease, hyper-eosinophilic 
syndrome, liver failure, and end-stage renal 
failure (eGFR <15 ml/min/1.73 m2). The study 
was approved by the local institutional board. 
Samples of peripheral venous blood were 
gathered from the patients who were admitted 
with the diagnosis of pulmonary embolism. 
Levels of fasting plasma glucose, creatinine, 
high-density lipoprotein cholesterol, 
triglyceride, and low-density lipoprotein 
cholesterol were determined using an automatic 
biochemical analyzer (Architect C8000, USA). 
We measured complete blood counts using 
concurrent optical and impedance 
measurements (Cell Dyn 3700; Abbott 
Diagnostics, Lake Forest, Illinois, USA). 
Hematologic measurements on K3EDTA-
anticoagulated whole blood were performed 
using a hematologic analyzer. 
Statistical analysis 
We analyzed the data using SPSS 18.0 
Statistical Package Software for Windows 
(SPSS Inc., Chicago, Illinois, USA). 
Quantitative and qualitative variables are 
expressed as mean ± standard deviation (SD) 
and numbers and percentages. A one-way 
analysis of variance (ANOVA) was preferred 
for parameters with homogenous distribution, 
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and post-hoc analyses were performed with 
Tukey’s HSD. For parameters with non-
uniform distribution or in case of inequality of 
variances, Kruskal–Wallis test served to 
compare variables across study subgroups. We 
used the Bonferroni-corrected Mann-Whitney 
U test for in-group differences. Variables with 
normal distribution were compared by T-test 
and expressed as mean ± SD. The Wilcoxon test 
was employed to assess the variations in 
eosinophil counts at the presentation and after 
the treatment in the pulmonary embolism 
group. The Spearman correlation analysis was 
used to assess the correlations between 
eosinophil counts and the right ventricle (RV) 
dysfunction on transthoracic echocardiogram 
or elevated cardiac troponin level with massive 
PE. A receiver operating curve (ROC) analysis 
served to find the predictive value of eosinophil 
count to distinguish between massive PE and 























The present study comprised a total of 183 
subjects, the control group (n=75), the sub-
massive group (n=64), and the massive group 
(n=44). All of the three groups showed similar 
baseline clinical characteristics and previous 
medications (Table 1). Regarding PE etiology, 
15 patients (13.9%) had cancer as an underlying 
disease; 32 (29.6%) had a history 
of immobilization after an operation and 4 
(3.7%) had immobilization after an accident; 5 
(4.6%) had genetic predisposition; 3 (2.8%) 
were in the postpartum period and 49 (45.4%) 
had no predisposing factor.  
Laboratory data other than those of white blood 
cells and eosinophil counts were similar 
between the groups (Table 2). The lowest 
eosinophil count was evident in the massive PE 
group whereas the control group had the highest 
value (p<0.001). The massive group showed 
the highest value of white blood cell counts 






























Age (mean ±SD) (years)) 59 ± 7 59 ± 16 63 ± 16 0.33 
Body mass index (kg/m2) 31 ± 1 30 ± 2 29 ± 1 0.24 
Systolic blood pressure 123 ± 14 118 ± 12 110 ± 11 0.09 
Diastolic blood pressure 74 ± 9 74 ± 9 71 ± 11 0.85 
Male/female 29/46 22/42 24/20 0.10 
Hypertension  34 (45%) 31 (48%) 18 (41%) 0.74 
Smoking 16 (21%) 10 (16%) 10 (23%) 0.59 
Diabetes mellitus 16 (21%) 10 (16%) 8 (18%) 0.69 
Acetyl salicylate  23 (31%) 14 (22%) 8 (18%) 0.26 
Calcium channel blocker 15 (20%) 11 (17%) 7 (16%) 0.83 
ACE inhibitor 5 (7%) 9 (14%) 8 (18%) 0.14 
ARB  13 (17%) 11 (17%) 4 (9%) 0.42 
B- blocker 21 (28%) 15 (23%) 4 (9%) 0.05 
ACE: angiotensin-converting enzyme, ARB: angiotensin receptor blocker, SD: standard deviation. 
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control group (<0.001).  
Kruskal-Wallis and Bonferroni-corrected 
Mann-Whitney U tests showed significantly 
different eosinophil counts between the 
massive PE and control groups (p <0.001), and 
between the massive and sub-massive PE 
groups (p =0.005). It also tended to vary 



































A CT scanner revealed that mean RV to LV 
dimension ratios were significantly higher in 
the massive PE group than those in the sub-
massive group (0.99±0.22 vs. 0.77±0.12, 
p<0.001, respectively). 
Spearman correlation test indicated that RV 
dysfunction or elevated cardiac troponin level 
was significantly correlated with the massive 











































Creatinine (mg/dl) 0.78 (0.58-2.14) 0.81 (0.5-7.6) 0.86 (0.65-1.76) 0.14 
Fasting plasma glucose 
(mg/dl) 
102 (76-413) 100 (47-228) 110 (68-280) 0.22 
LDL-cholesterol (mg/dl) 119 (60-195) 114 (51-278) 119 (33-210) 0.47 
Triglyceride (mg/dl) 133 (37-212) 131 (48-294) 145 (45-338) 0.12 
Eosinophil counts (K/uL) 0.174 (0.003-0.853) 0.121 (0.002-0.620) 0.050 (0.003-0.383) <0.001 
Basophil counts (K/uL) 0.065 (0.010-0.580) 0.064 (0.007-0.183) 0.059 (0.008-0.288) 0.68 
Mean ± S.D. 
HDL-cholesterol (mg/dl) 45 ± 10 47 ± 12 44 ± 10 0.28 
Hemoglobin (g/dL) 13.4 ± 1.5 12.6 ± 1.9 13.0 ± 1.8 0.14 
Platelet counts (K/uL) 240 ± 60 230 ± 70 225 ± 75 0.09 
MPV (fL) 8.1 ± 1.5 7.7 ± 1.5 7.5 ± 1.2 0.09 
PDV (GSD) 17.7 ± 1.2 17.7 ± 1.4 17.9 ± 0.0.9 0.67 
RDW (%) 16.5 ± 1.9 16.7 ± 2.8 16.7 ± 2.3 0.79 
Monocyte counts (K/uL) 0.52 ± 0.19 0.60 ± 0.30 0.60 ± 0.19 0.53 
Lymphocyte counts 
(K/uL) 
2.13 ± 0.79 1.95 ± 0.86 2.05 ± 1.20 0.11 
WBC counts(K/uL) 7.35 ± 1.63 8.76 ± 2.64 9.19 ± 3.98 0.001 
Total cholesterol (mg/dl) 195 ± 47 200 ± 38 202 ± 51 0.72 
LDL: low-density lipoprotein, HDL: High-density lipoprotein, MPV: Mean platelet volume, PDW: Platelet distribution 
width, RDW: Red cell distribution width, WBC: White blood cell. 
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count had an inverse correlation with the 
presence of massive PE (r=-0.36, p<0.001). 
A receiver operating curve (ROC) analysis 
yielded the sensitivity and specificity of 
eosinophil count for the discrimination of the 
massive PE group. At a cut-off value of 
<0.125u/mm3, the sensitivity and specificity for 
eosinophil count were 73% and 59%, 
respectively, for determination of massive PE 

















Figure 1. A receiver operating curve (ROC) 
analysis of eosinophil count for differentiating 
massive PE from sub-massive PE. At the cut-
off value of <0.125 u/mm3, sensitivity and 
specificity of eosinophil count were 73 % and 
59 % for determination of massive  PE 
respectively.  (AUC = 0.715, 95% CI, 0.616-
0.815). (AUC: area under the curve; CI: 
Confidence interval). 
 
All patients in the sub-massive PE group 
received heparin therapy. As for the massive PE 
group, heparin treatment was administered in 
five patients with active cancer, twelve patients 
in the postoperative period, two patients in the 
post-accident immobilization period, and five 
patients who refused thrombolytic consent, and 
thus the remaining 20 patients received 
thrombolytic therapy. During six months of the 
follow-up, four patients (3.6%) died either 
during the in-hospital stay (two patients) or 
during the follow-up after hospitalization (two 
patients).  
The eosinophil count increased significantly, 
regardless of treatment modality, one week 
after the treatment compared to presentation 
with PE (0.112 (0.003-0.853) vs. (0.144 (0.011-
0.914), p=0.01, respectively). 
 
Discussion 
The association of decreased eosinophil count 
with the severity of PE was the principal finding 
of our study. It was significantly lower in the 
massive PE than the sub-massive PE and the 
control groups. As far as we know, this is the 
first study to show that a lower peripheral 
eosinophil count may support massive PE 
rather than sub-massive PE in patients with 
acute PE. Regarding the clinical aspect of this 
finding, decreased eosinophil counts should be 
a new therapeutic target in the massive PE sub-
group. 
Pulmonary embolism accounts for 10% of all 
causes of hospital deaths [11]. Patients with 
pulmonary embolism are clinically classified 
into massive and sub-massive patients based on 
blood pressure, right ventricular functions, high 
cardiac markers, and radiologically affected 
vascular bed [9].  
It remains unclear how eosinophils are involved 
in the pathogenesis of thrombus formation. 
Neurotoxins, eosinophil cationic proteins, and 
major basic proteins released from eosinophils 
can cause endothelial damage resulting in 
fibrosis, thrombosis, and infarction [12]. Also, 
the enzyme peroxidase and the major basic 
protein released from eosinophilic granules 
may lead to thrombus formation by directly 
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activating platelets and inhibiting 
thrombomodulin [13]. By means of another 
mechanism, tissue factors released from 
eosinophils bind to coagulation factor 7 and 
directly initiate the coagulation cascade [14]. 
The literature has reported the effects of 
eosinophils on thrombus formation in patients 
with the idiopathic hyper-eosinophilic 
syndrome, and the rare causes of arterial 
thrombosis and cardio-embolic stroke in 
childhood [1,15].   
Coronary atherosclerotic plaques showed 
higher eosinophil concentration in the red 
thrombus, while the number of eosinophils in 
peripheral blood showed a negative correlation 
with the troponin count [13]. Furthermore, 
lower eosinophil counts were reported in 
myocardial infarction compared to those in 
unstable angina pectoris [16]. In addition, lower 
eosinophil counts were associated with a worse 
prognosis in patients undergoing percutaneous 
coronary intervention [17]. Mackman et al. 
investigated whether eosinophils were present 
in human coronary artery thrombus in patients 
with acute myocardial infarction of native 
vessels or stent thrombosis. They revealed that 
thrombi from female patients with previous 
stent thrombosis contained significantly 
elevated numbers of eosinophils. They also 
discussed which subgroups of patients could 
benefit most from an eosinophil-inhibition 
approach [18]. 
Therefore, a reverse correlation may exist 
between eosinophil counts and the burden of 
thrombi. However, eosinophil concentration 
has not been studied in aspirated PE thrombus. 
In light of the evidence that, for eosinophils, 
higher concentrations in coronary thrombi and 
less number in the systemic circulation are 
associated with the severity of acute coronary 
events, the fact that we detected fewer 
eosinophils in massive PE compared to sub-
massive PE can be explained by the 
accumulation of eosinophils in the thrombus 
burden and thus their decreased number in the 
systemic circulation.  
The present study showed that lower eosinophil 
counts may support the diagnosis of massive PE 
at acute presentation. This study also showed 
that eosinophil counts increased after treatment 
regardless of the treatment modality. Due to the 
retrospective nature of our study, the 
association of this finding with clinical 
outcomes is unclear. After conducting further 
studies on larger populations, these findings 
may prove useful both in the determination of 
massive PE and in the preference of treatment 
modalities including lytic therapy or 
mechanical interventions. 
The main limitations of this study consist in the 
fact that it is a single-centered study with a 
retrospective design. Direct evidence was 
absent on the accumulation of eosinophils in the 
pulmonary emboli material. Another limitation 
lies in the fact that measurements were 
unavailable for the major basic protein, 
eosinophilic cationic protein, peroxidase, and 
other cytokine levels that may interfere with 
thrombosis. The retrospective design of the 
study did not allow us to determine cardiac 
enzymes, RV dysfunction data on transthoracic 
echocardiogram, and arterial blood gas 
parameters for all patients. 
Conclusion 
In conclusion, our study demonstrated an 
inverse relationship between the eosinophil 
count, a cheap and widespread hemogram 
parameter in peripheral blood, and the severity 
of PE. The counts were lower in massive PE 
than sub-massive PE. Therefore, lower 
eosinophil counts in an acute PE may lead 
physicians to suggest a higher probability of 
massive PE, and taking it as a predictor factor 
may require initiation of lytic therapy or 
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mechanical interventions. This finding needs to 
be supported by larger, prospective, and 
multicenter studies. 
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